Analysts Are Bullish on These Healthcare Stocks: LPCN, NBY

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lipocine (NASDAQ: LPCN) and NovaBay Pharma (NYSE: NBY) with bullish sentiments.

Lipocine (NASDAQ: LPCN)

Roth Capital analyst Michael Higgins reiterated a Buy rating on Lipocine (NASDAQ: LPCN) today and set a price target of $38. The company’s shares opened today at $4.02.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -15.4% and a 28.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Sucampo Pharmaceuticals, and Juniper Pharmaceuticals.

Lipocine has an analyst consensus of Strong Buy, with a price target consensus of $24.33.

NovaBay Pharma (NYSE: NBY)

In a report released today, Scott Henry from Roth Capital reiterated a Buy rating on NovaBay Pharma (NYSE: NBY), with a price target of $5.50. The company’s shares opened today at $2.80.

According to TipRanks.com, Henry is a 1-star analyst with an average return of -1.8% and a 42.4% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Synergy Pharmaceuticals Inc, and Avadel Pharmaceuticals plc.

NovaBay Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $5.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.